Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Conference on Alzheimer’s reveals several advances in the field

In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Sci...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Event: Drug Development – Serendipity or Science

Drug development is a challenging journey, we will discuss questions you may not even consider asking. SDS and Medicon Village welcome you to an engaging afternoon.

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Novavax is developing a vaccine candidate against Covid-19 and seasonal flu

A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvan...

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Inget statligt stöd för fetmaläkemedel – aktien för läkemedelsjättar pressas

Trump-administrationen slopar Bidens förslag om att om att inkludera fetmaläkemedel i sjukförsäkringen Medicare. Det innebär ett bakslag för Novo Nordisk och El...

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Pharmaevent lockade internationella deltagare

Under tisdagen arrangerade Life Science Sweden eventet Pharma Outsourcing. I år var deltagare från över 10 länder på plats i Life City i Hagastaden.

TFS Trial Form Support AB

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Amrop Malmö AB